Vanda says its drug can halve vomiting risk in patients using GLP-1snews2025-11-18T11:57:39+00:00November 18th, 2025|Endpoints News|
Zymeworks and Jazz tout HER2 bispecific success in first Phase 3 readoutnews2025-11-17T20:44:06+00:00November 17th, 2025|Endpoints News|
Nuvalent shares Phase 1/2 data for ALK inhibitor that could battle with Pfizer’s Lorbrenanews2025-11-17T11:50:47+00:00November 17th, 2025|Endpoints News|
Genmab cans another ADC from ProfoundBio deal in area of J&J’s Ambrx buyoutnews2025-11-17T10:04:19+00:00November 17th, 2025|Endpoints News|
Sofinnova secures $750M for eleventh fund focused on drugmakers nearing the clinicnews2025-11-17T01:01:20+00:00November 17th, 2025|Endpoints News|
Zhejiang Doer Biologics unveils first-in-class tri-agonist for high lipidsnews2025-11-14T17:56:23+00:00November 14th, 2025|Endpoints News|
Bristol Myers, J&J’s next-gen blood thinner fails key trial in another setback for factor XInews2025-11-14T16:16:30+00:00November 14th, 2025|Endpoints News|
Cartesian to pause work in form of lupus, despite trial successnews2025-11-14T15:48:11+00:00November 14th, 2025|Endpoints News|
Medicxi, which backed Vicebio and Versanis, closes new €500M biotech fundnews2025-11-14T11:57:42+00:00November 14th, 2025|Endpoints News|
AbbVie, Alphabet’s Calico end 11-year partnership in aging researchnews2025-11-13T16:09:58+00:00November 13th, 2025|Endpoints News|
